NCT02723721View on ClinicalTrials.gov

Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Lentigo Maligna
Interventions
DRUG

Picato gel

apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.

Trial Locations (8)

93000

AP-HP Hopital Avicenne, Bobigny

Unknown

AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt

Hôpital du Morvan, Brest

CHRU de Lille, Lille

CHU de Nantes, Nantes

Hôpital Pontchaillou, Rennes

CHU de Saint Etienne, Saint-Etienne

06000

CHU de Nice, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT02723721 - Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face | Biotech Hunter | Biotech Hunter